Kevin Guest was named Chief Executive Officer of Usana Health Sciences Inc. As of November 14, 2026, Usana Health Sciences Inc has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from January 8, 2026 to February 11, 2026, naming 1 appointment (Form 8-K, January 8, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like Usana Health Sciences Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Usana Health Sciences Inc reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-01-08 to 2026-02-11. They name 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Usana Health Sciences Inc files it.
Also on the record for Usana Health Sciences Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 13, 2026 | Stake report, Schedule 13G, by Nantahala Capital Management, LLC | 5.35% of the class | 5%+ stakes | Source |
| August 13, 2026 | Stake report, Schedule 13G/A, by Renaissance Technologies LLC | 5.19% of the class | 5%+ stakes | Source |
| March 30, 2026 | Stake report, Schedule 13D/A, by Myron W. Wentz | 40.1% of the class | 5%+ stakes | Source |
| March 27, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| January 21, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 4.4% of the class | 5%+ stakes | Source |
| January 21, 2026 | Stake report, Schedule 13G/A, by Dimensional Fund Advisors LP | 4.6% of the class | 5%+ stakes | Source |
| October 14, 2025 | Stake report, Schedule 13G/A, by PZENA INVESTMENT MANAGEMENT LLC | 6.6% of the class | 5%+ stakes | Source |
| October 9, 2025 | Stake report, Schedule 13G, by Dimensional Fund Advisors LP | 5% of the class | 5%+ stakes | Source |
| July 29, 2025 | Stake report, Schedule 13G/A, by The Vanguard Group | 5.43% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Usana Health Sciences Inc now and the warning signs.
Free to see. No signup.
Keep reading
More on Usana Health Sciences Inc and the records around it.
Usana Health Sciences Inc elsewhere on the record
- 5%+ stake filings Nov 2026
- Who owns it
Companies that share a holder
- PZENA INVESTMENT MANAGEMENT LLC also filed stake reports on 37 other companies: ADVANCE AUTO PARTS INC (Oct 2026), Globant S.A. (Oct 2026), Koppers Holdings Inc. (Oct 2026)
- Renaissance Technologies LLC also filed stake reports on 48 other companies: Bolt Biotherapeutics, Inc. (Nov 2026), CORE MOLDING TECHNOLOGIES INC (Nov 2026), Hello Group Inc. (Nov 2026)
- Nantahala Capital Management, LLC also filed stake reports on 73 other companies: AEON Biopharma, Inc. (Nov 2026), CURIS, INC. (Nov 2026), DarioHealth Corp. (Nov 2026)
Watch Usana Health Sciences Inc
Get an email when Usana Health Sciences Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Usana Health Sciences Inc?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Usana Health Sciences Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Usana Health Sciences Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
11 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-02-11 | Reported | not named in the filing | 8-K/A, 2026-02-11 | ||
| 2026-01-08 | In | Chief Executive Officer | 8-K, 2026-01-08 |
Who leads Usana Health Sciences Inc, as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Executive Officer: Kevin Guest, appointed (filed 2026-01-08).
New leaders reset buying decisions — get the Full Report on Usana Health Sciences Inc: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Executive Officer at Usana Health Sciences Inc, with the record behind each one.
Find candidates like Chief Executive Officer at Usana Health Sciences IncEvery change, in the filing's words
Reported
that Jim Brown stepped down as the Company's Chief Executive Officer and President, and that Kevin Guest, the Company's Chairman of the Board, reassumed the role of Chief Executive Officer.
- At the time of the Initial 8-K, the Compensation Committee of the Board (the "Compensation Committee") had not determined the compensation arrangements for Mr. Brown or Mr. Guest.
- Mr. Brown On February 5, 2026, the Company and Mr. Brown entered into a Transition Agreement (the "Transition Agreement") which documents his transition from the Company's Chief Executive Officer and President to a strategic advisor to Mr. Guest and the Company from January 7, 2026, through December 31, 2026 (the "Transition Period").
- Mr. Brown's employment as a strategic advisor will end on December 31, 2026 (the "Separation Date").
- While Mr. Brown serves as a strategic advisor during the Transition Period, he will receive payment of (i) his base salary of $825,000; (ii) his earned, but unpaid, executive bonus for the 2025 fiscal year, payable in accordance with the Company's standard practices; and (iii) medical and other benefits, similar to those available to eligible employees of the Company.
- Mr. Brown will remain eligible to exercise all equity awards issued to him, which vest prior to the Separation Date.
- All equity awards issued to Mr. Brown, which have not vested as of the Separation Date will be cancelled.
Appointed: Kevin Guest, Chief Executive Officer
In August 2014, Mr. Guest was appointed President of USANA and in August 2015, he was appointed Co-Chief Executive Officer.
- On January 8, 2026, USANA Health Sciences, Inc. (the "Company" or "USANA") announced a leadership transition pursuant to which Jim Brown stepped down as Chief Executive Officer and President of the Company.
- Mr. Brown will remain with the Company in an advisory role for a period at the discretion of the Board of Directors.
- As part of this transition, Kevin Guest, 63, who currently serves as Executive Chairman of the Board and previously served as Chief Executive Officer, will reassume the role of Chief Executive Officer.
- Mr. Guest will also continue to serve as Chairman of the Board.
- The Compensation Committee of the Board of Directors has not yet determined the material terms of Mr. Brown's compensation arrangements in connection with his separation from the Company.
- The Compensation Committee expects to make such determinations shortly.
- The Compensation Committee expects to make such determinations shortly.
- In the interim, Mr. Guest will continue to receive his previously approved compensation as Executive Chairman of the Board.
- Following the Company's acquisition of the media, video, and event-productions company FMG Productions founded by Mr. Guest, he became a full-time employee of the Company and was promoted to Vice President of Media and Events in February 2004.
Tools for this story
Each opens in a new tab, filled in for Usana Health Sciences Inc. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
